Medical/Pharmaceuticals
SinoUnited Health Attracts International Patients as China Emerges as Global Medical Tourism Destination
SHANGHAI, April 14, 2026 /PRNewswire/ -- From CAR-T Cell Therapy and cardiac interventions to health checkups and dental care, China's medical capabilities have increasingly drawn international patients in recent years—underscoring the country's rising influence in the global healthcare landscape...
2026-04-15 09:17
3650
SST001, an α-syn PET tracer from Mabwell's incubated company SynuSight Biotech, received NMPA approval to initiate a clinical trial
SHANGHAI, April 15, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that18F-FD4 (R&D code: SST001), an α-synuclein (α-syn) targeted PET tracer independently developed by its incubated company SynuSight Bio...
2026-04-15 08:00
5167
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
MELBOURNE, Australia and INDIANAPOLIS, April 15, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed with TLX101-Tx (¹³¹I-iodofalan) in Telix's pivotal IPAX BrIGHT trial[1], marking the first radiopharmaceutical...
2026-04-15 06:50
5814
Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds
MELBOURNE, Australia and Indianapolis, April 15, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) ("Telix") is pleased to announce that it has successfully priced and upsized its 1.50 per cent convertible notes due 2031 to be issued by its wholly-owned subsidiary, Telix ...
2026-04-15 06:35
7070
Mexican company Farmacias Similares brings Dr. Simi to Tokyo in Japan debut
A pop-up store is being opened by Farmacias Similares in Shibuya, which is in the heart of Tokyo. TOKYO, April 15, 2026 /PRNewswire/ -- Dressed as a samurai and with his trademark energetic attitude, Dr. Simi—the face of Farmacias Similares— greets curious visitors stopping by the company's pop-...
2026-04-15 06:00
4082
Advances in Parkinson's Disease Cell Therapy: XellSmart Launches a Multicenter Phase II Clinical Trial Following Encouraging Phase I Results
SUZHOU, China, April 14, 2026 /PRNewswire/ -- In April 2026, XellSmart officially launches its multicenter Phase II registrational clinical trial of the "Clinical-Grade, Allogeneic, Off-the-Shelf, iPSC-Derived, Dopaminergic Neural Progenitor Cell Therapy (XS411) for Primary Parkinson's Disease". ...
2026-04-14 22:00
5001
TCI Biotech Returns to Vitafoods Europe 2026 with Five Provocations for the Nutraceutical Industry and a Glimpse of the Future
BARCELONA, Spain, April 14, 2026 /PRNewswire/ -- TCI Biotech, the global CDMO+ leader in health and wellness innovation, will return to Vitafoods Europe 2026 at booth 3F40, Fira Barcelona Gran Via, armed with five bold challenges to the industry's most stubborn pain points. Building on 46 years ...
2026-04-14 22:00
4308
Phrontline Biopharma Presents Preclinical Data for TJ106, a Biparatopic HER2 Dual-Payload ADC, at American Association for Cancer Research Annual Meeting 2026
Data Demonstrate Activity in HER2-Low and ADC-Resistant Tumor Models, Supporting Advancement Toward IND SHANGHAI and SUZHOU, China, April 14, 2026 /PRNewswire/ -- Phrontline Biopharma today announced the presentation of preclinical data for TJ106, a next-generation biparatopic HER2-targeting ant...
2026-04-14 21:08
4084
NYSE Content Update: OpenLoop Health Debuts At-Home Sleep Apnea Test with 98% Accuracy
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, April 14, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begi...
2026-04-14 21:03
6800
Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma
SYDNEY, April 14, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Com...
2026-04-14 21:02
4898
Telix Refinances Convertible Bonds
MELBOURNE, Australia and INDIANAPOLIS, Ind., April 14, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) ("Telix") today launches an offering of US$550 million convertible notes due 2031 to be issued by its wholly-owned subsidiary, Telix Pharmaceuticals (Investments) Inc....
2026-04-14 16:32
6523
Senhwa Biosciences Secures Strategic Backing from Global Investor GEM with Up to NT$500 Million to Accelerate AI-Driven Drug Development
TAIPEI and SAN DIEGO, April 14, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company announced today the signing of a Memorandum of Understanding (MOU) with GEM YIELD BAHAMAS LIMITED, an affiliate of the global investment firm Global Emerging Mark...
2026-04-14 15:11
5052
triSure NIPT Debuts in Taiwan, Expanding Non-Invasive Prenatal Screening Beyond Aneuploidy
All-in-one approach integrates chromosomal analysis, single-gene disorder
screening, and maternal carrier screening from a single blood draw.
TAIPEI, April 14, 2026 /PRNewswire/ -- At the prestigious Taiwan Association
of Obstetrics and Gynecology
2026-04-14 11:30
5283
Kelun-Biotech Announces Results from the SKB264-II-06/MK-2870-002 Study of Sacituzumab Tirumotecan (Sac-TMT) in Gynecologic Oncology Presented at 2026 SGO
CHENGDU, China, April 14, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that results from both the ovarian cancer cohort and the cervical cancer cohort of Phase II study SKB264-II-06/MK-2870-002 of the TROP2 ADC sacit...
2026-04-14 08:00
7315
Boston Aesthetics Appoints Brandon Nye as Chief Executive Officer to Drive Next Phase of Commercial Growth
IRVINE, Calif., April 13, 2026 /PRNewswire/ – Boston Aesthetics today announced the appointment of Brandon Nye as Chief Executive Officer, effective immediately. Nye will lead the company's strategic growth initiatives, commercial expansion, and operating execution as Boston Aesthetics enters its...
2026-04-13 23:00
4348
Sirtex Medical's DOORwaY90 Study Demonstrates 100% Local Tumor Control with SIR-Spheres®, Setting a New Benchmark in Y-90 for HCC
The DOORwaY90 study met its prespecified co-primary endpoints, achieving a best
overall response rate (ORR) of 99%
WOBURN, Mass., April 13, 2026 /PRNewswire/ -- Sirtex Medical ("Sirtex")
2026-04-13 21:00
4900
PANVIS STAR Vascular Interventional Robotic System Redefines Mechanical Thrombectomy
BEIJING, April 13, 2026 /PRNewswire/ -- In 2021, there were 11.96 million new stroke cases worldwide, with ischemic stroke (IS) accounting for 65.3%. China has an estimated 17.8 million stroke survivors, 86.8% of which are ischemic. For large vessel occlusion (LVO), mechanical thrombectomy (MT) i...
2026-04-13 20:41
4138
Noah Medical Launches Deep-Dive Research Series on Medical Robotics Value
Why the World's Leading Medical Robotics Companies Put Clinical Value First This article serves as a foundational study for the Noah Medical deep-dive series, aiming to help investors establish a core framework for assessing value in the medical robotics industry. HONG KONG, April 13, 2026 /PRNe...
2026-04-13 17:40
3587
PANVIS STAR Vascular Interventional Robotic System Redefines Mechanical Thrombectomy
BEIJING, April 13, 2026 /PRNewswire/ -- In 2021, there were 11.96 million new stroke cases worldwide, with ischemic stroke (IS) accounting for 65.3%. China has an estimated 17.8 million stroke survivors, 86.8% of which are ischemic. For large vessel occlusion (LVO), mechanical thrombectomy (MT) i...
2026-04-13 17:14
4015
Caliway's Fat Reduction Drug CBL-514 Phase 2 Clinical Results Accepted by ASJ. CBL-0204's Demonstrated Efficacy and Safety Gain Further Academic Recognition
* Clinical results from Caliway's CBL-0204 Phase 2b study of its fat reduction drug candidate CBL-514 for localized fat reduction have been accepted by theAesthetic Surgery Journal (ASJ), a leading academic journal in aesthetic medicine and plastic surgery. * Following the publication of CBL-...
2026-04-13 16:34
6084
Week's Top Stories
Most Reposted
Visa redefines its role in travel with the global expansion of Visa Destinations
[Picked up by 336 media titles]
2026-06-30 10:00Sustainable Tourism Academy Celebrates 3,000-User Milestone in First Year with ASEAN Expansion and New Language Support
[Picked up by 323 media titles]
2026-06-29 12:41
Agoda rolls out suite of new features focused on real-time updates and smarter trip planning
[Picked up by 321 media titles]
2026-07-01 10:00
On-us Brings Real-Time Smart E-Vouchers to Google Wallet, Giving Marketers a Live Read on Customer Behavior
[Picked up by 319 media titles]
2026-06-30 11:00
Avnet Brings Ecosystem Together to Scale Edge AI in Singapore
[Picked up by 305 media titles]
2026-06-30 09:00Most Read
JINRO, the World's No. 1 Soju Brand, Partners with V of BTS
2026-07-03 08:00
13922
/UPDATE TO VIDEO -- New York Stock Exchange/
2026-07-01 01:36
7116
NYSE Content Update: Mobility Global Marks First Day as Public Company
2026-07-01 21:22
6371
